Bacillus coagulans MTCC 5856 and No Significant Safety Parameter Changes

• Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study

  • 2015-12
  • RCT · n = 36
  • Nutrition Journal 15(1)
  • • M. Majeed
    • K. Nagabhushanam
    • Sankaran Natarajan
    • A. Sivakumar
    • Furqan Ali
    • A. Pande
    • Shaheen Majeed
    • S. K. Karri

  • PubMed: 26922379
  • DOI: 10.1186/s12937-016-0140-6

  11 Insights on

  • No Significant Safety Parameter Changes

  • High evidence
  • Highly Cited

  Laboratory parameters, anthropometric and vital signs were within the normal clinical range during the 90 days of supplementation in placebo and B. coagulans MTCC 5856 group.

  Effect

  Neutral

  Effect size

  Small

  Dose

  2 × 10(9) cfu/day